Borderline leprosy in darker-skinned individuals presents with patches of skin that may be hypopigmented or erythematous, which can be challenging to diagnose due to the color of the skin. The condition involves both sensory loss and nerve damage, leading to skin lesions and potential deformities if left untreated. Treatment typically includes a multi-drug therapy regimen of dapsone, rifampicin, and clofazimine, with regular monitoring to prevent complications such as nerve damage or secondary infections.